Roche Holding AG Current Ratio 2006-2019 | RHHBY

Current and historical current ratio for Roche Holding AG (RHHBY) from 2006 to 2019. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Roche Holding AG current ratio for the three months ending December 31, 2019 was .
Roche Holding AG Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2019-12-31 $31.46B $24.28B 1.30
2019-06-30 $32.24B $23.39B 1.38
2018-12-31 $32.97B $23.55B 1.40
2018-06-30 $30.04B $23.38B 1.29
2017-12-31 $32.09B $22.52B 1.43
2017-06-30 $27.09B $20.93B 1.29
2016-12-31 $29.11B $22.95B 1.27
2016-06-30 $27.43B $25.20B 1.09
2015-12-31 $29.33B $24.74B 1.19
2015-06-30 $26.77B $23.06B 1.16
2014-12-31 $34.05B $25.29B 1.35
2014-06-30 $31.47B $20.13B 1.56
2013-12-31 $31.48B $17.01B 1.85
2013-06-30 $27.25B $17.20B 1.58
2012-12-31 $33.48B $21.57B 1.55
2012-06-30 $28.67B $19.26B 1.49
2011-12-31 $31.97B $18.36B 1.74
2011-06-30 $28.50B $17.67B 1.61
2010-12-31 $26.54B $14.39B 1.84
2010-06-30 $25.06B $15.93B 1.57
2009-12-31 $35.54B $20.38B 1.74
2009-06-30 $35.67B $23.93B 1.49
2008-12-31 $35.75B $11.21B 3.19
2008-06-30 $33.22B $11.21B 2.96
2007-12-31 $35.72B $12.06B 2.96
2007-09-30 $0.00B 0.00
2007-06-30 $33.58B $9.97B 3.37
2006-12-31 $32.68B $10.14B 3.22
2006-06-30 $28.52B $7.12B 4.01
2005-12-31 $28.64B $7.63B 3.75
2005-06-30 $25.25B $6.48B 3.90
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $279.418B $61.869B
Roche Holding AG is a research-based, product-focused organization dedicated to the discovery and early clinical development of pharmaceuticals and drugs, fine chemicals and vitamins, fragrances and flavors, diagnostic equipment and liquid crystals. The Company distributes its products throughout Europe, the United States, Asia and Latin America.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $339.589B 14.84
Merck (MRK) United States $187.177B 14.22
Novartis AG (NVS) Switzerland $185.475B 15.44
Pfizer (PFE) United States $176.138B 10.76
Novo Nordisk (NVO) Denmark $141.488B 24.29
Eli Lilly (LLY) United States $130.559B 22.59
Bristol-Myers Squibb (BMY) United States $123.757B 11.74
AstraZeneca (AZN) United Kingdom $114.895B 24.73
AbbVie (ABBV) United States $108.417B 8.21
Sanofi (SNY) France $107.453B 12.77
GlaxoSmithKline (GSK) United Kingdom $92.874B 11.78
Bayer (BAYRY) Germany $52.894B 7.62
H Lundbeck (HLUYY) Denmark $5.897B 10.25
Innoviva (INVA) United States $1.164B 8.03